- Home
- FOXF vs SNDX Comparison
FOXF vs SNDX Comparison
Compare FOXF & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOXF
- SNDX
- Stock Information
- Founded
- FOXF 2007
- SNDX 2005
- Country
- FOXF United States
- SNDX United States
- Employees
- FOXF N/A
- SNDX N/A
- Industry
- FOXF Motor Vehicles
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- FOXF Consumer Discretionary
- SNDX Health Care
- Exchange
- FOXF Nasdaq
- SNDX Nasdaq
- Market Cap
- FOXF 1.2B
- SNDX 1.1B
- IPO Year
- FOXF N/A
- SNDX 2016
- Fundamental
- Price
- FOXF $26.02
- SNDX $14.75
- Analyst Decision
- FOXF Buy
- SNDX Strong Buy
- Analyst Count
- FOXF 7
- SNDX 10
- Target Price
- FOXF $34.86
- SNDX $38.40
- AVG Volume (30 Days)
- FOXF 390.8K
- SNDX 2.0M
- Earning Date
- FOXF 10-30-2025
- SNDX 11-04-2025
- Dividend Yield
- FOXF N/A
- SNDX N/A
- EPS Growth
- FOXF N/A
- SNDX N/A
- EPS
- FOXF N/A
- SNDX N/A
- Revenue
- FOXF $1,441,852,000.00
- SNDX $77,933,000.00
- Revenue This Year
- FOXF $8.61
- SNDX $585.73
- Revenue Next Year
- FOXF $6.08
- SNDX $94.17
- P/E Ratio
- FOXF N/A
- SNDX N/A
- Revenue Growth
- FOXF 7.16
- SNDX 2126.66
- 52 Week Low
- FOXF $17.95
- SNDX $8.58
- 52 Week High
- FOXF $44.27
- SNDX $22.50
- Technical
- Relative Strength Index (RSI)
- FOXF 36.10
- SNDX 47.48
- Support Level
- FOXF $27.30
- SNDX $15.71
- Resistance Level
- FOXF $28.98
- SNDX $16.50
- Average True Range (ATR)
- FOXF 1.02
- SNDX 0.81
- MACD
- FOXF -0.32
- SNDX -0.36
- Stochastic Oscillator
- FOXF 8.14
- SNDX 2.73
About FOXF Fox Factory Holding Corp.
Fox Factory Holding Corp is a designer, manufacturer, and marketer of performance-defining products and systems used predominantly on bikes, Side-by-Sides, on-road vehicles with and without off-road capabilities, off-road vehicles and trucks, ATVs, snowmobiles, specialty vehicles and applications, motorcycles, and commercial trucks. Its business operates under the FOX, FOX RACING SHOX, and RACE FACE brands. Geographically, it derives a majority of revenue from North America and also has a presence in Asia, Europe, and the Rest of the World.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.